



Recent advances in the use of Anti-TNF α therapy for the treatment of juvenile idiopathic arthritis

Andrea Taddio, Marco Cattalini, Gabriele Simonini & Rolando Cimaz

To cite this article: Andrea Taddio, Marco Cattalini, Gabriele Simonini & Rolando Cimaz (2016): Recent advances in the use of Anti-TNF α therapy for the treatment of juvenile idiopathic arthritis, Expert Review of Clinical Immunology, DOI: [10.1586/1744666X.2016.1146132](https://doi.org/10.1586/1744666X.2016.1146132)

To link to this article: <http://dx.doi.org/10.1586/1744666X.2016.1146132>



Accepted author version posted online: 25 Jan 2016.



Submit your article to this journal [↗](#)



Article views: 6



View related articles [↗](#)



View Crossmark data [↗](#)

Publisher: Taylor & Francis

Journal: *Expert Review of Clinical Immunology*

DOI: 10.1586/1744666X.2016.1146132

Recent advances in the use of Anti-TNF α therapy for the treatment of juvenile idiopathic arthritis

Andrea Taddio, Marco Cattalini, Gabriele Simonini and Rolando Cimaz

- 1) Institute for Maternal and Child Health - IRCCS "Burlo Garofolo" – University of Trieste, Trieste, Italy
- 2) Immunology and Rheumatology Department, Pediatric Clinic, University of Brescia and Spedali Civili di Brescia, Brescia, Italy
- 3) Anna Meyer Childrens Hosp, Florence, Italy

Summary

Juvenile idiopathic arthritis (JIA) encompasses a group of diseases of unknown etiology having in common arthritis in at least 1 joint that persists for 6 weeks and begins before 16 years of age, with other conditions excluded. With a prevalence of 1 per 1,000 children in the USA, JIA is the most common pediatric rheumatic illness and a major cause of acquired childhood disability. During the last 20 years, the advent of host immune response modifiers known as biologic agents, in particular the anti-TNF α agents (etanercept, infliximab, adalimumab), which directly inhibit the action of pro-inflammatory mediators, has revolutionized the treatment and the expected outcome of JIA. This article highlights treatment indications of anti-TNF α drugs and their more frequent side effects in JIA patients.

Key words: Juvenile Idiopathic Arthritis, Etanercept, Infliximab, Adalimumab, Anti-TNF α agents,, Side effects

Anti-TNF α treatment in JIA

Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease in childhood and may cause of disability and long-term impairment. JIA is not a single disease and encompasses different clinical conditions sharing an age of onset < 16 years and arthritis lasting at least six weeks.

Although nomenclature and classification need to be reconsidered, the most recent classification is based on the International League of Associations for Rheumatology (ILAR) Pediatric Task Force [1] which has divided the disease into the following different entities: Systemic JIA; Persistent Oligoarthritis; Extended Oligoarthritis; Rheumatoid Factor Negative Polyarthritis; Rheumatoid Factor Positive Polyarthritis; Psoriatic Arthritis; Enthesitis-Related Arthritis and Undifferentiated arthritis.

However, it is clear that systemic JIA, which encompasses about 10% of all JIA types, is a distinct clinical entity completely different from all the other forms. The high expression of pro-inflammatory cytokines in patients' sera [2], the presence of fever in all patients and the response to IL-1 or IL6 blockade [3,4] suggest that the disease might be considered an autoinflammatory disease, rather than an autoimmune disorder. Moreover, anti-TNF α treatment is not usually beneficial for patients with systemic JIA, suggesting again that these patients suffer from a different disease [5].

On the other hand, more than 70% of patients with JIA are affected by Oligo- or Polyarthritis and only these forms will be taken into account in this review.

Historically treatment has involved Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), systemic and Intra-Articular Corticosteroids, and Methotrexate. In the last decades therapeutic approaches for children with unremitting disease have included the use of drugs blocking TNF α . These treatments

have the capacity to suppress one of the main pro-inflammatory cytokine: TNF α , which is involved in systemic inflammation and many autoimmune disorders.

The more commonly used anti-TNF α agents include: Infliximab, a chimeric monoclonal antibody; Etanercept, a fusion protein; and Adalimumab, a fully human monoclonal antibody.

Infliximab and Etanercept seemed to provide a rapid and sustained reduction in disease activity in children with refractory JIA, but etanercept is usually still the first treatment choice among anti-TNF α drugs. Lovell et al. demonstrated, in fact, that treatment with Etanercept at the dose of 0.4 mg per kilogram twice weekly led to significant improvement in patients with active polyarticular JIA [6]. The same results were then confirmed by Kietz et al. on a smaller cohort of patients. The use of Etanercept showed to be safe and effective over a two and four year period [7].

It was also observed that the use of Etanercept in combination with Methotrexate, or other Disease Modifying Antirheumatic Drugs (DMARDs) was well tolerated and highly effective when compared with Etanercept alone, and years later Horneff et al. [8] also demonstrated that the combination therapy was more effective than monotherapy in achieving clinical remission.

Prince et al. firstly demonstrated that a single weekly double dose of Etanercept could be as effective as the twice weekly administration [9]; the same results were then confirmed by Horneff et al. in an elegant multicenter 12 week trial [10]. On the other hand, a higher dose of etanercept (>0,8 mg/kg twice weekly), even if considered safe and well tolerated did not seem to offer any additional benefit in those patients with inadequate response to standard dose.

The excellent clinical response to Etanercept, the safety profile of the drug and data suggesting a reduction in radiographic progression in JIA [11] have suggested to promote a trial with an early aggressive treatment characterized by two arms: the first with Methotrexate only, the second with a combination treatment including Methotrexate, Etanercept and Prednisone. However, there was no statistical difference between the two groups in achieving the primary end point (clinical remission at 6 months) [12]. The rate of clinical inactive disease at two years, among JIA patients treated with Etanercept, is about 50% [13].

Infliximab, although frequently used in Rheumatoid Arthritis, has not been widely employed in JIA. The first studies, however, reported a very low infliximab dosage (3-4 mg/kg) with weak clinical effectiveness; in the following years it has been suggested that the drug should have been used with a higher dosage (>6 mg/kg) in order to obtain significant results. In fact, Gerloni et al. demonstrated a good clinical response to Infliximab in combination with Methotrexate in patients who did not previously respond to Methotrexate treatment alone [14]. However these data were not later confirmed by an international, randomized multicenter placebo controlled double blind trial, that did not find any clinical difference between patients treated with Infliximab and those treated with placebo [15].

On the other hand Infliximab, as discussed in the next appropriate section, is very effective in JIA-related uveitis.

Anti-TNF α treatment seems to be particularly useful in those patients with Enthesitis Related Arthritis (ERA), a JIA subgroup corresponding to juvenile spondyloarthritis and characterized by arthritis and enthesitis, often associated with HLA-B27 positivity. In these patients both Infliximab and Etanercept seem to be effective. In particular, Etanercept has been recently associated to clinical remission in ERA patients [16] and Adalimumab has also been shown efficacious; their use is suggested for those patients who did not previously respond to DMARDs [17]. For inflammatory bowel disease-related arthritis infliximab seems to be the first choice.

Adalimumab is the relative more recent anti-TNF α biologic agent used in JIA. After the recognition of a possible role of Etanercept in uveitis development among patients with JIA [18], Adalimumab was firstly used in patients with JIA-related uveitis with good results [19]. Its efficacy in JIA was reported by Lovell et al. in a cohort of patients naive to treatment with other anti-TNF α agents [20], while Katsicas *et al.* showed good results in patients who already had failed another anti-TNF α agent [21]. According to the 2011 ACR recommendations, Adalimumab is suggested after failure of a first anti-TNF α drug, usually Etanercept, or as a first biologic DMARDs if uveitis is present [22];

however recently Adalimumab has been demonstrated safe and useful also as first biologic agent in JIA [23]

Despite the even larger use of biological treatment, data on their comparison are lacking.

Although Etanercept and Adalimumab are considered equally effective, in daily practice etanercept is most often prescribed while Adalimumab is mainly preferred when uveitis is present [24] even if patients with a history of uveitis presented higher risks for uveitis events while taking both etanercept and adalimumab in other reports [25]. In a recent systematic review, all available efficacy data from randomised controlled trials performed in JIA with biological agents were analysed, but indirect comparisons identified no significant differences in short-term efficacy [26]. Therefore, for now, paediatric rheumatologist has to rely on observational data and safety, practical and financial arguments. Head-to-head trials are still required to decide on the best biological treatment for JIA.

Side effects of anti-TNF α agents

The introduction of biologics in the treatment of patients with JIA have clearly revolutionized our approach to these disease and dramatically improved the outcome of affected children. Still, some concerns exist on the safety of these drugs, in particular regarding the long-term side effects, given the limited period of time since they have been introduced. The evaluation of long-term safety of anti-TNF α is of the utmost importance for rheumatologists, since a consistent part of children with JIA will enter adulthood with active disease and will need ongoing medical treatment [27]. Unfortunately, safety data on the use of these drugs in children come from very heterogeneous studies, in terms of population selected, ILAR category of the patients recruited, study design (i.e randomized controlled trials, retrospective cohort analysis, patients registries, case series and case reports), drug regimen, definition of adverse events and serious adverse events, and events reporting system. Furthermore, given the JIA prevalence, even the largest studies available in the literature may not have considered enough patients to catch rare events. These are very important biases to consider when trying to draw conclusions on the safety of these drugs in children with JIA [28].

From a theoretical point of view, concerns exist on the possible correlation between the anti-TNF α blockers and the occurrence of infections and tumors, given the functions of TNF α on the immune system [29]. Serious adverse events (SAEs) have been reported in 3-4% of patients during the first phases of RCTs, while longer term studies reported a wider variability in the incidence of SAEs, from 2 to more than 20 events/100 patients/year [6; 12; 15; 20; 30-42]. The more commonly reported SAEs are injection site and infusion reactions. Adverse Events (AEs) occurred in almost a third of the patients enrolled in the RCTs and were reported with an incidence from less than 50 cases/100patient/year to more than 2500 cases/100patients/year in other studies. The more commonly described AEs were local injection site reactions or infusion reactions and infections. Again, this very wide variability in the incidence of AEs and SAEs is probably caused by the extreme heterogeneity of the studies published, as already discussed. Table 1 reports a selection of studies with data on long-term safety of the anti-TNF α drugs.

Autoimmune disorders

Few reports focus on specific SAEs and AEs. Krishnan et al. evaluated the risk to develop inflammatory bowel disease (IBD) in patients receiving anti-TNF α for JIA or RA, reviewing the files from the Food and Drug Administration Adverse Event Reporting System. A total of 55 patients with JIA developed IBD: 50 patients were on Etanercept, 2 on Adalimumab and 3 on Infliximab. With the application of the Naranjo score, in the majority of cases the association between the drug and the IBD was considered “probable” [43,44]. Methodological biases hamper the strength of this study in determining a clear link between IBD and anti-TNF α therapy, and further studies may clarify if the development of IBD could be a possible “paradoxical reaction” in children with JIA treated with TNF α -blockers. Of note, it has been recently demonstrated in a large German JIA cohort that among patients treated with methotrexate (MTX) the IBD incidence was significantly lower compared with patients not treated with MTX, while Etanercept monotherapy (but not the combination of ETN and MTX) was associated with an increased incidence of IBD.

This indirectly suggests both a protective effect of MTX in IBD development of patients with JIA and possible effect in Etanercept in IBD incidence [45].

Infectious complications

Toussi et al. systematically reviewed the incidence of infections in children with JIA treated with anti-TNF α drugs: severe infections occurred in up to 9% of patients treated, with the respiratory tract and musculoskeletal system as the main sites of infections. Mild infections occurred more frequently, from 8% to 97% percent of patients, mainly in the upper respiratory tract. Even though the majority of studies considered failed to report the etiology of the infections, *Streptococcus pyogenes* and *Staphylococcus aureus* were the bacterial pathogens most often identified, while herpes simplex virus and varicella zoster virus were the most frequent among viral infections [46]. Very few cases of *M. tuberculosis* were described, probably thanks to the application of tuberculosis screening in all JIA patients prior to receiving a TNF α blocker. This screening was first recommended for adults with RA, and later applied also in children with JIA [22; 47]. Of note, annual screening of children at low risk of TB with an initial negative TB test is considered inappropriate (level D) [48].

Walters et al. prospectively followed for up to 12 months 56 JIA patients, 20 of whom received TNF α blockers, while the remaining 36 did not receive immunosuppressive therapy. There was no difference in the infection-rate between TNF and no-TNF receiving patients. Although this study was biased by the relatively low number of patients and a short follow-up, it suggests that patients with JIA may have an increased risk of infection, independently from the underlying therapy, compared to children without JIA [49-50].

Malignancy

The possible correlation between anti-TNF α treatment and the onset of tumors is the more relevant concern on the long-term safety of these drugs. Indeed, in the first reports tumors were rarely reported as SAEs. It was therefore worrisome that in 2008 the FDA issued a black box warning about the possible association between the use of anti-TNF agents in children and the development

of malignancies. This warning was the base of a study by Diak et al. published two years later, which identified through the FDA Adverse Reporting System 48 cases of malignancies among children with JIA or IBD receiving TNF blockers [51]. This report includes biases such as the combination of different diseases (i.e. JIA and IBD) and the lack of consideration of other concomitant immunosuppressant drugs. Moreover, no data were available at the time of publication on the background incidence of malignancy in patients with JIA. Beukelman *et al.* subsequently compared children with JIA, treated with methotrexate and/or an anti-TNF α , with children with attention deficit hyperactivity disorders. The authors found that children with JIA were at higher risk of developing malignancy, and this risk was not increased by the association of a TNF α blocker [52]. Similar results were obtained by Nordstrom *et al.*, who found that the incidence rates of cancer were respectively 67.0 and 23.2 cases/100,000 person-years for JIA and non-JIA children, with a 3-fold increased risk of malignancy in biologics-naïve JIA children, compared to non JIA children [53]. These studies seem therefore to suggest that JIA patients are at higher risk of developing cancer, independently from the anti-TNF α treatment. Given the low incidence of both JIA and malignancy in childhood, and the possible long delay between the onset of JIA and cancer, very large cohorts of patients should be followed for long periods before reaching firm conclusions. Still, pediatric rheumatologists should keep an active surveillance on their patients with JIA, on whatever treatment used, to early identify the development of malignancy.

JIA-related uveitis

The association between Juvenile Idiopathic Arthritis and ocular inflammation was firstly described by Ohm in 1910 and subsequently confirmed by several authors. Data regarding the incidence of uveitis in JIA (4–24%) differ considerably due to the recruitment of different medical centres and to geographical variations. A recent meta-analysis estimated worldwide incidence at about 8.3% [54]. To date, JIA-related uveitis represents the most common cause of pediatric uveitis in developed countries. Children affected by JIA who develop ocular involvement do so in up to 50% of cases within 3 months and in up to 90% within 4 years from the diagnosis. Only 2-7% of patients are

diagnosed with uveitis before the onset of arthritis. Ocular inflammation may also appear for the first time during adulthood. Children affected by uveitis may also present a severe articular involvement, however the presence of ocular inflammation does not seem to affect the long-term prognosis of joint involvement and the clinical course of the two conditions may be completely independent as well.

JIA-associated uveitis typically presents a non-granulomatous bilateral involvement with chronic course. Anterior chamber is primarily affected, isolated or in the context of panuveitis, whereas posterior involvement alone is less common.

Considering patients affected by JIA and according to ILAR, an ophthalmologic evaluation should be performed at the time of diagnosis and periodically repeated regardless of presence or absence of symptoms. The frequency of ocular examination is defined on the basis of the subtype of arthritis, the age at onset and the presence of ANA.

Compared to adults, childhood uveitis is characterized by poor prognosis and higher risk of secondary complications, with considerable socioeconomic burden. Even if the uveitis remission rate may be up to 70-80%, uveitis still represents the third leading cause of blindness in developed countries. Among children suffering from JIA, visual complications have been reported in up to 80% of patients after 3 years and in almost 100% of patients after 20 years of disease. These develop as a consequence of persistent or recurrent ocular inflammation, but also as result of chronic steroid treatment [55-56].

The most common complications include: cataract (19-81% of patients), glaucoma (8-38%), band keratopathy (7-10%), synechiae (8-75%), cystoid macular oedema (8-42%), ocular hypotony (19%), retinal detachment, retinal ischemia and optic atrophy [57]. Up to 30% of patients show reduced visual acuity and up to 10% develop blindness. From 28% to 70% of affected children may require surgical therapy.

Treatment for non-infectious uveitis is based on a “step-by-step” approach, in order to control local inflammation, achieve a corticosteroid-sparing effect and reduce the risk of visual complications

[58-59]. Local steroid therapy associated to mydriatics is proposed for mild-to-moderate conditions, especially in case of anterior involvement. Severe ocular inflammation may instead require oral or intravenous systemic steroid treatment.

In corticosteroid-resistant and corticosteroid-dependent cases systemic immunomodulatory agents should be considered. For patients intolerant or non-responders to methotrexate, biologic therapies represent a valid option.

Considering anti-TNF α treatments, the therapies approved for paediatric population comprise infliximab, etanercept and adalimumab. Despite presenting a similar mechanism of action, these molecules showed different efficacy in uveitis treatment. A recent meta-analysis highlighted a superior efficacy of Adalimumab and Infliximab when compared to Etanercept, which is not routinely recommended [59]. Infliximab represents an efficient short-term treatment for uveitis [60]. A retrospective clinical trial documented a significant resolution of ocular inflammation in 16 patients undergoing MTX and Infliximab evaluated at 3, 6, 9 and 12 months [61]. However, efficacy in long-term treatment seems to be limited, with subsequent possibility of ocular relapse [62-63].

If favorable outcomes have been reported for Etanercept in articular involvement, its effectiveness in ocular inflammation seems to be limited. Infliximab superiority on Etanercept was reported in adults affected by JIA-related uveitis [64]. A randomized controlled trial involving pediatric patients did not show significant difference between the administration of Etanercept and placebo. Therefore, Etanercept is not currently recommended as first systemic biologic therapy for uveitis [65].

On the other hand, several clinical trials suggested the efficacy of Adalimumab in the treatment of uveitis [19; 66]. We reported the superiority of Adalimumab compared to Infliximab in maintaining long-term ocular remission among 33 children affected by chronic uveitis [67]. This evidence has been confirmed by a following multicentre study involving 108 children affected by JIA-related arthritis. Both Infliximab and Adalimumab provided good safety and efficacy data, however

Adalimumab was more likely to achieve long-term remission, especially if administered as first TNF α inhibitor [68]. We also showed, even if limited to a relatively small group, a better efficacy of Adalimumab when used as first anti-TNF α treatment in childhood chronic uveitis. [69].

A recent meta-analysis provides evidence that, when a previous course of anti-TNF α failed to induce/maintain remission in chronic uveitis of children, switching to a new anti-TNF α treatment (Adalimumab and Infliximab) has a favorable effect in the improvement of intraocular inflammation [70].

Although not yet approved, Golimumab has been described as a promising new therapeutic option for severe uveitis in those patients who have not responded to other biologics [71]

Expert Commentary

JIA is one of the most common autoimmune disorders. In the last decades great improvements in disease control and sequelae prevention have been reached. This is due mostly to the use of anti-TNF α drugs. However, some aspects still remain to be clarified. The safety of anti-TNF α use has been demonstrated in the last years and the associated risk to develop autoimmune disorder, malignancy and infections appears now very low, at least in the short term.

The most common problem for clinicians dealing with JIA patients treated with anti-TNF α drugs is the possible loss of effect during time. This is probably due to the endogenous production of antibodies against anti-TNF α drugs, and sometimes the drug needs to be switched with another biologic.

It is also not still clear which anti-TNF α should be used first and which should be considered the best treatment for specific JIA subgroups. This is mostly due to the lack of comparative studies between anti-TNF α drugs among the same JIA subgroup of patients. Moreover the presence of newer biologics available on market does not allow a complete evaluation of all therapeutic strategies and, in the next years, the presence of biosimilars, with the same expected clinical but lower production costs, will probably modify the drug prescriptions and the list of approved indications.

Five-year view

JIA medical management has never been clearly and widely established; however in the last years expert guidelines for JIA treatment have been formulated [22]. The most relevant aspect was the fact that, despite some reports suggesting a better clinical effect of early aggressive treatment with biologics [12], the TNF α agents still remain in the second line treatment after failure of NSAIDs, corticosteroids injection where possible and Methotrexate treatment. Although early aggressive therapy for JIA may be an interesting strategy, published evidence so far is too weak to recommend this as a general accepted therapeutic strategy [72; 73]. It is also important to underline that a wide and non selective use of anti-TNF α agents could probably not be affordable for the national health systems.

Finding one or more predictive markers of response to anti-TNF α agents has a great importance in the clinical practice in order to identify a subset of patients with a higher chance of response, who could benefit from an early treatment. However these data are scarce at the moment so far. Until now, research studies for identification of treatment response markers were mostly aimed to evaluate the role of single nucleotide polymorphisms (SNPs) among genes involved in cytokine pharmacodynamics and pharmacokinetics.

Several studies have identified polymorphisms associated to anti-TNF α response, however no one of these markers reached an adequate level of evidence to be used in the clinical practice [74-76].

It is common to experience a progressive lack of effect of anti-TNF α treatments during time. This is probably due to the production of antibodies against anti-TNF α drugs which bind effector binding sites [77-78]. In order to avoid such a complication, some authors suggest to add a small dose of Methotrexate (usually 5 mg/week irrespectively of the body surface) with the goal to decrease autoantibody production; however, results are still debated.

Finally, another recent development is the presence on the market of biosimilars, biological medical products which are a copy of an original product that is manufactured by a different company. Biosimilars are a version of original biologic products, and can be manufactured when the original

product [patent](#) expires. They are now entering in the use of autoimmune chronic disorders, and their lower costs might probably improve their use in clinical settings. However it is not still demonstrated if their effectiveness is similar to the original products, and it is important to underline that they are not yet approved for JIA.

Key issues

- Juvenile Idiopathic Arthritis is one of the most common autoimmune diseases in childhood and is characterized by the onset < 16 years and presence of arthritis lasting more than 6 weeks.
- The use of biologic DMARDs, in particular the anti-TNF α agents, has increased in the last years, but their application is currently suggested only for patients who do not respond to first line treatment (NSAIDs, intra-articular corticosteroids, Methotrexate).
- Etanercept is usually the first treatment choice among biologic DMARDs, but Adalimumab represents an effective alternative.
- Anti-TNF α agents are safe, but a relatively higher risk of infections has been reported among patients on long term treatment; in particular potential reactivation of latent tuberculosis seems to be particularly threatening. For these reasons, attention should be made in ruling out latent tuberculosis before starting such treatments, and special attention during febrile infections should be given while receiving anti-TNF α treatments.
- Some reports suggest a particular association of anti-TNF α treatment with occurrence of autoimmune diseases. In particular, a possible association between the use of etanercept and uveitis development has been suggested.
- Anti-TNF α treatment has been reported to be particular effective also in treating uveitis, the most common extra-articular complication of JIA.

Financial and competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript.

This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

References

Reference annotations

* Of interest

** Of considerable interest

1. Foeldvari I, Bidde M. Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol 2000;27:1069-1072.
2. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-1486.
3. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396-2406
4. De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385-2395
5. Cimaz R, Von Scheven A, Hofer M. Systemic-Onset Juvenile Idiopathic Arthritis: the changing life of a rare disease. Swiss Med Wkly 2012;9:142w13582.
6. **Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med. 2000;342:763-9.

Children with polyarticular JIA were enrolled to receive etanercept at the dose of 0,4 mg/kg subcutaneously twice a week. The first phase of the study was open and the second

part double blind. Patients receiving Etanercept presented a significant improvement and resulted well tolerated.

7. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2006;54:1987-94.
8. **Horneff G, De Bock F, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. *Ann Rheum Dis* 2009;68:519-25.

The study demonstrates the efficacy and the tolerance of combination therapy with Etanercept and Methotrexate. Moreover it proves that a combination therapy seems to be more effective in inducing clinical remission than monotherapy alone.

9. Prince FH, Twilt M, Jansen-Wijngaarden NC, et al. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. *Ann Rheum Dis* 2007;66:704-5.
10. Horneff G, Ebert A, Fitter S, et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. *Rheumatology (Oxford)*. 2009;48:916-9.
11. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2008;26:688-92.
12. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. *Arthritis Rheum*. 2012;64:2012-21.
13. Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. *J Rheumatol* 2013;40(2):192-200

14. Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. *Arthritis Rheum* 2005;52:548-53.
15. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. *Arthritis Rheum* 2007;56:3096-106.
16. Horneff G, Foeldvari I, Minden K, et al. Efficacy and safety of etanercept in patients with Enthesitis-Related Arthritis category of juvenile-idiopathic arthritis: results from a phase III randomized, double blind trial. *Arthritis Rheumatol* 2015;67: 2240-9.
17. Otten MH, Prince FH, Twilt M, et al. Tumor necrosis factor-blocking agents for children for enthesitis-related arthritis – data from dutch arthritis and biologicals in children register 1999-2010. *J Rheumatol* 2011; 38:2258-63.
18. *Saurenmann RK, Levin AV, Feldman BM, et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF α agents. *J Pediatr* 2006;149:833-6.
- The paper shows a relative high risk of new onset uveitis in patients treated with Etanercept.***
19. Tynjälä P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. *Rheumatology (Oxford)* 2008;47:339-44.
20. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. *N Engl J Med* 2008;359:810-20.
21. Katsicas MM, Russo RA. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. *Clin Rheumatol* 2009;28:985-8.
22. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety

- monitoring of therapeutic agents for the treatment of arthritis and systemic features. *Arthritis Care Res (Hoboken)* 2011;63:465-82.
23. Schmeling H, Minden K, Foeldvari I, et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. *Arthritis Rheumatol* 2014;66:2580-9.
 24. Anink J, Otten MH, Gorter SL, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? *Rheumatology (Oxford)* 2013 Sep;52(9):1674-9.
 25. Foeldvari I, Becker I, Horneff G. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. *Arthritis Care Res (Hoboken)* 2015;67:1529-35.
 26. Otten MH, Anink J, Spronk S, et al. Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons. *Ann Rheum Dis* 2013;72:1806-12.
 27. Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. *Rheumatology (Oxford)* 2000;39:198-204.
 28. Ringold S, Hendrickson A, Abramson L, et al. Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. *Arthritis Care Res* 2015;67:529-37
 29. Puimège L, Libert C, Van Hauwermeiren F. Regulation and dysregulation of tumor necrosis factor receptor-1. *Cytokine Growth Factor Rev* 2014;25:285-300.
 30. Tynjälä P, Vahasalo P, Tarkiainen M et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicenter randomised open-label clinical trial. *Ann Rheum Dis* 2011;70:1605-12.
 31. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. *Arthritis Rheum* 2009;60:2794-804.

32. Zuber Z, Rutkowska-Sak L, Postepski J et al. Etanercept treatment in juvenile idiopathic arthritis: the Polish registry. *Med Sci Monit* 2011;17:SR35-SR42.
33. Prince FHM, Twilt M, Rt Cate, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. *Ann Rheum Dis* 2009;68:635-41.
34. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. *Arthritis Rheum* 2008;58:1496-504.
35. Ruperto N, Lovell DJ, Cuttica R et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. *Ann Rheum Dis* 2010;69:718-22
36. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. *Ann Rheum Dis* 2008;67:1145-52
37. Horneff G, Burgos-Vargas R, Constantin T et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. *Ann Rheum Dis* 2014;73(6):1114-22.
38. Minden K, Niewerth M, Zink A et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. *Rheumatology* 2012;51:1407-15
39. Schmeling H, Minden K, Foeldvari I et al. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. *Arthritis Rheumatol* 2014;66:2580-9.
40. Tarkiainen M, Tynjälä P, Vähäsalo P et al Lahdenne P. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting. *Rheumatology* 2015;54:1170-6.

41. Windschall D, Müller T, Becker I, et al. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. Clin Rheumatol 2015;34:61-9.
42. Klotsche J, Niewerth M, Haas JP, et al. [Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis \(JIA\)](#). Ann Rheum Dis. 2015 Apr 29.
43. Krishnan A, Stobaugh DJ, Deepak P. Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis. Rheumatol Int 2015;35:661-8.
44. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
45. Barthel D, Ganser G, Kuester RM, et al. Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis treated with biologics. J Rheumatol 2015;42:2160-65.
46. *Toussi SS, Pan N, Walters HM et al. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor- α inhibitors: systematic review of the literature. Clin Infect Dis 2013;57:1318-30.
- This is a systematic review confirming the possibility of severe infections, although rare among patients taking anti-TNF α agents.***
47. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
48. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken) 2013;65:1551-63.

49. Walters HM, Pan N, Lehman TJ, et al. A prospective study comparing infection risk and disease activity in children with juvenile idiopathic arthritis treated with and without tumor necrosis factor-alpha inhibitors. *Clin Rheumatol* 2015;34:457–464.
50. Beukelman T, Xie F, Chen L et al. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum* 2012;64:2773–2780.
51. *Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. *Arthritis Rheum* 2010;62:2517-24.

The paper shows a relative higher risk of malignancies among patients taking anti-TNF α agents, however the risk does not seem higher in consideration of the underlying disease.

52. Beukelman T, Haynes K, Curtis JR, et al. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. *Arthritis Rheum* 2012;64:1263-71.
53. Nordstrom BL, Mines D, Gu Y, et al. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents. *Arthritis Care Res* 2012;64:1357-64.
54. Miserocchi E, Fogliato G, Modorati G, et al. Review on the worldwide epidemiology of uveitis. *Eur J Ophthalmol* 2013;23:705-717.
55. Anesi SA, Foster CS. Importance of recognizing and preventing blindness from juvenile idiopathic arthritis - associated uveitis. *Arthritis Care and Research* 2012;64:653-7.
56. Ozdal PC, Vianna RN, Deschenes J. Visual outcome of juvenile rheumatoid arthritis-associated uveitis in adults. *Ocul Immunol Inflamm* 2005;13:33-8.
57. Heiligenhaus A, Niewerth M, Ganser G, et al. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. *Rheumatology* 2007;46:1015-9.
58. Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. *Autoimmunity Reviews* 2010;9:674-83.

59. Simonini G, Druce K, Cimaz R, et al. Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. *Arthritis Care Res* 2014;66:1073- 84.
60. Holzinger D, Frosch M. New treatment approaches in juvenile idiopathic arthritis. *Int J adv Rheumatol* 2009; 7:1-7.
61. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic chronicnoninfectious uveitis in children: retrospective case series with long-term follow up. *Am J Ophtalmol* 2007; 144: 844-9.
62. Simonini G, Zannin ME, Caputo R et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. *Rheumatology (Oxford)* 2008; 47:1510-4.
63. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. *J AAPOS* 2008;12: 611-3.
64. Tynjala P, Lindahl, Honkanen V et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. *Ann Rheum Dis* 2007;66: 548-50.
65. Smith JA, Thompson DJ, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. *Arthritis Rheum* 2005;53:18-23.
66. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in children. *Br J Ophtalmol* 2007;91:319-24.
67. **Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. *Arthritis Care Res (Hoboken)* 2011;63:612-8. This study reveals a better efficacy of Adalimumab compared to infliximab in treating chronic anterior uveitis related to JIA.

68. Zannin ME, Birolo C, Gerloni VM, et al. safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1 year follow up data from the Italian Registry. *J Rheumatol* 2013;40:74-9.
69. Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF α therapy in childhood chronic uveitis. *Pediatric Rheumatol Online J* 2013;15:11-16.
70. Simonini G, Druce K, Cimaz R, et al. Does switching anti-TNF α biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach. *Semin Arthritis Rheum* 2014;44:39-46.
71. Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. *Ocul Immunol Inflamm* 2014;22:90-95.
72. Ringold S, Weiss PF, Colbert RA, et al. [Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis.](#) *Arthritis Care Res (Hoboken)*. 2014;66(7):1063-72.
73. Webb K, Wedderburn LR. [Advances in the treatment of polyarticular juvenile idiopathic arthritis.](#) *Curr Opin Rheumatol*. 2015;27(5):505-10.
74. Modesto C, Patiño-García A, Sotillo-Piñeiro E, et al. TNF α promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic-onset juvenile idiopathic arthritis. *Scand J Rheumatol* 2005;34:451-4.
75. Schmeling H, Wagner U, Peterson A, et al. Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis. *Clin Exp Rheumatol* 2006;24:103-8.
76. Cimaz R, Cazalis MA, Reynaud C, et al. IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors. *Ann Rheum Dis* 2007;66:900-4.

77. Real-Fernández F, Cimaz R, Rossi G, et al. Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization. *Anal Bioanal Chem* 2015 Jul 26.
78. Kosmac M, Avcin T, Toplak N, et al. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. *Pediatr Res* 2011;69:243

ACCEPTED MANUSCRIPT

author	type of study	# of pts	main drug	duration of tx (range)	pts/yrs	other drugs	SAEs (per 100 pt/years)	Type of SAEs (per 100 pt/years)	AEs	Type of AEs	Comments
Lovell et al., 2008 [20]	open label RCT	171	ADA	16 wks	27,3*/29,3**	±MTX	3(10)*/ 4(10)**	3 RTI 1 g.i. infection 2 lab abnormalities 1 HSV infection 2 VZV infection 1 abdominal pain 1 hydrocephalus	422(1550)*/ 447(1530)**	902 injection-site reactions 157 URTI 74 viral infection	*+MTX/**noMTX only AEs possibly related to study drug were reported
	double-blind withdrawal RCT			32 wks	23,3*/25**		1(10)*/0**		389(2310)*/ 324(2630)**		
	open-label extension			NA	127,4*/102,6* *		7(10)*/2**		694(540)*/ 581(570)**		
Ruperto et al., 2010 [35]	open label CT	78	INF	114,1	NA	plus MTX	17	6 worsening arthritis 2 pneumonia 2 infusion reaction 1 tuberculosis	71	URTI (>20% of patients) infusion reactions (25 patients) ANA and anti-DNA onset	
Tynjala et al., 2011 [30]	open-label RCT	20	INF	54 wks	20,8	plus MTX	NA	NA	100(48)	36(17) URTI 3(1) g.i. 14(7) lab abnormalities 2(1) infusion reaction	polyarticular JIA only
Zuber et al., 2011 [32]	national registry	188	ETA	72mths	393	DMARDs	6 (2)	optic disc oedema leukopenia MAS TBC+CMV infection	1162 (296)	RTI (24,8) HSV infection (9,7) gastroenteritis (8) urinary infection (5,1) meningitis (0,5) influenza (0,8) optic disc edema (4,3)	
Minden et al., 2012 [38]	national registry (JuMBO)	346	ETA	4.1 yrs (1-10)	598	DMARDs ±biologics	54 (9)	infections (1.7) 1 death for suicide 2IBD 2 psoriasis 4 uveitis	NA	NA	

								1 SLE 1 neuromyelitis			
Schmeling et al., 2014 [39]	national registry (BiKeR)	289 (130*,159**)	ADA		NA			1 Anxiety* 1 Urinary tract infection* 1 Diabetes Mellitus* 1 Concussion* 1 Nephritis* 1 Urticaria* 1 Paresthesia** 1 Abnormal lab** 1 Crohn's disease** 1 Intestinal resection**		26*/18**Respiratory tract infection 4*/1** g.i. tract infection 13*/4 other infections 1* varicella 1** zoster 19*/13** g.i. complains 4*/4** injection site pain 5*/4** blod test abnormalities 2*/2** headache 1*/1** mood disorder 11*/17**miscellaneous	* biologics-naive/** biologic switchers
				1,2 yrs (0,58-1,88)*		DMARDs	6 (3,2)*	112(59)*			
				1,13 yrs (0,61-1,94)**		DMARDs ±biologics	5 (2)**	110 (44,8)**			
Klotsche et al., 2015 [42]	national registry (BiKeR+JuMBO)	1734(1414*, 320**)	ETA*,ADA*		4461*/493**	DMARDs ±biologics	199 (4,5)*/23 (4,7)**	6 (0,09)*/2 (0,27)** malignancies 4 (0,06)* deaths (2 sepsis, one MAS, one carditis)	NA	255(5,72)*/56(11,36)** infections 21(0,5)*/1(0,2)** uveitis 12(0,27)*/1(0,2)** IBD 17(0,38)*/0** blood disorders	* ETA/** ADA
Windschall et al., 2015 [41]	national registry (BiKeR)	1374	ETA		2805,38	DMARDs ±biologics	108(21,13)	NA	762(142,02)	NA	
Tarkiainen et al., 2015 [40]	national registry	348	ETA*,INF**,ADA***	NA	710*/591**/188***	DMARDs ±biologics	213*/214**/94***	infections (3,9) labworks abnormalities (3,1) administration site reactions (0,9) neurologic/psychiatric disorders (0,9)	(169*/215**/167***)		*ETA/**INF/**ADA

Table 1: a selection of papers reporting on safety of antiTNF blockers, selected based on design of the study, number of patients recruited, year of publication (ETA: etanercept; INF: infliximab; ADA: adalimumab; DMARDs: disease-modifying anti-rheumatic drugs; MTX: methotrexate; U/RTI: upper/respiratory tract infections; IBD: inflammatory bowel disease)